Thank you for downloading this publication. Please let us know why you chose this publication:
Why are you interested in this publication?
What organisation do you represent?
You will only need to complete this form once per browser/device
How do you prefer to read or receive publications?

We may contact you for feedback on the publication you have downloaded. If you do not want to be contacted, please leave the email field blank. Your information will never be shared with any third party.

Donate
English En EnglishEn FrançaisFr
  • What we do
    • Diseases
    • Policy development and advocacy
    • Research
    • Learning
  • Our expertise
  • Where We Work
    • Africa
    • Burkina Faso
    • Chad
    • Ethiopia
    • Mozambique
    • Nigeria
    • South Sudan
    • Uganda
    • Asia
    • Cambodia
    • Myanmar
    • Thailand
  • Projects
    • Project database
    • Featured projects
    • Past projects
  • Publications
  • Media centre
    • Newsletters
    • News
    • Blog
    • Videos
    • Webinars
    • Press and media
    • Photo stories
    • Voices of experience
  • About us
    • Who we are
    • Governance
    • Aid transparency
    • Dr Sylvia Meek
    • Annual reviews
    • Policies and procedures
    • Careers
    • Tenders
    • Contact us
    • Malaria Consortium U.S.
  • Support us
  • Home
  • »
  • Resources
  • »
  • Publications
  • »
  • Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systemic review and meta-analysis

Share this page

Resources

Latest

Publications

Publication Date:
14/05/2020

Type:
Journal article
Publication

Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systemic review and meta-analysis
Author(s): Daniel A. Pfeffer, Benedikt Ley, Rosalind E. Howes, Patrick Adu, Mohammad Shafiul Alam, Pooja Bansil, Yap Boum II, Marcelo Brito, Pimlak Charoenkwan, Archie Clements, Liwang Cui, Zeshuai Deng, Ochaka Julie Egesie, Fe Esperanza Espino, Michael E. von Fricken, Muzamil Mahdi Abdel Hamid, Yongshu He, Gisela Henriques, Wasif Ali Khan, Nimol Khim, Saorin Kim, Marcus Lacerda, Chanthap Lon, Asrat Hailu Mekuria, Didier Menard, Wuelton Monteiro, Franc�ois Nosten, Nwe Nwe Oo, Sampa Pal, Duangdao Palasuwan, Sunil Parikh, Ayodhia Pitaloka Pasaribu, Jeanne Rini Poespoprodjo, David J. Price, Arantxa Roca-Feltrer, Michelle E. Roh, David L. Saunders, Michele D. Spring, Inge Sutanto, Kamala Ley-Thriemer, Thomas A. Weppelmann, Lorenz von Seidlein, Ari Winasti Satyagraha, Germana Bancone, Gonzalo J. Domingo, Ric N. Price

Publication Date:
14/05/2020
Type:
Journal article

Background

The radical cure of Plasmodium vivax and P. ovale requires treatment with primaquine or tafenoquine to clear dormant liver stages. Either drug can induce haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, necessitating screening. The reference diagnostic method for G6PD activity is ultraviolet (UV) spectrophotometry; however, a universal G6PD activity threshold above which these drugs can be safely administered is not yet defined. Our study aimed to quantify assay-based variation in G6PD spectrophotometry and to explore the diagnostic implications of applying a universal threshold.

 

Methods and findings

Individual-level data were pooled from studies that used G6PD spectrophotometry. Studies were identified via PubMed search (25 April 2018) and unpublished contributions from contacted authors (PROSPERO: CRD42019121414). Studies were excluded if they assessed only individuals with known haematological conditions, were family studies, or had insufficient details. Studies of malaria patients were included but analysed separately. Included studies were assessed for risk of bias using an adapted form of the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Repeatability and intra- and interlaboratory variability in G6PD activity measurements were compared between studies and pooled across the dataset. A universal threshold for G6PD deficiency was derived, and its diagnostic performance was compared to site-specific thresholds. Study participants (n = 15,811) were aged between 0 and 86 years, and 44.4% (7,083) were women. Median (range) activity of G6PD normal (G6PDn) control samples was 10.0 U/g Hb (6.3–14.0) for the Trinity assay and 8.3 U/g Hb (6.8–15.6) for the Randox assay. G6PD activity distributions varied significantly between studies. For the 13 studies that used the Trinity assay, the adjusted male median (AMM; a standardised metric of 100% G6PD activity) varied from 5.7 to 12.6 U/g Hb (p < 0.001). Assay precision varied between laboratories, as assessed by variance in control measurements (from 0.1 to 1.5 U/g Hb; p < 0.001) and study-wise mean coefficient of variation (CV) of replicate measures (from 1.6% to 14.9%; p < 0.001). A universal threshold of 100% G6PD activity was defined as 9.4 U/g Hb, yielding diagnostic thresholds of 6.6 U/g Hb (70% activity) and 2.8 U/g Hb (30% activity). These thresholds diagnosed individuals with less than 30% G6PD activity with study-wise sensitivity from 89% (95% CI: 81%–94%) to 100% (95% CI: 96%–100%) and specificity from 96% (95% CI: 89%–99%) to 100% (100%–100%). However, when considering intermediate deficiency (<70% G6PD activity), sensitivity fell to a minimum of 64% (95% CI: 52%–75%) and specificity to 35% (95% CI: 24%–46%). Our ability to identify underlying factors associated with study-level heterogeneity was limited by the lack of availability of covariate data and diverse study contexts and methodologies.

 

Conclusions

Our findings indicate that there is substantial variation in G6PD measurements by spectrophotometry between sites. This is likely due to variability in laboratory methods, with possible contribution of unmeasured population factors. While an assay-specific, universal quantitative threshold offers robust diagnosis at the 30% level, inter-study variability impedes performance of universal thresholds at the 70% level. Caution is advised in comparing findings based on absolute G6PD activity measurements across studies. Novel handheld quantitative G6PD diagnostics may allow greater standardisation in the future.

Published in PLOS Medicine

Click here to download

Keywords: Research | Use of evidence | Malaria | Diagnosis | Quality improvement | SDG3

 

 

« Back to Publications

Sign up for our publications newsletter here:

Sign up for our newsletters here:

  • What we do
    • Diseases
    • Policy development and advocacy
    • Research
    • Learning
  • Our expertise
  • Where We Work
    • Africa
    • Burkina Faso
    • Chad
    • Ethiopia
    • Mozambique
    • Nigeria
    • South Sudan
    • Uganda
    • Asia
    • Cambodia
    • Myanmar
    • Thailand
  • Projects
    • Project database
    • Featured projects
    • Past projects
  • Publications
  • Media centre
    • Newsletters
    • News
    • Blog
    • Videos
    • Webinars
    • Press and media
    • Photo stories
    • Voices of experience
  • About us
    • Who we are
    • Governance
    • Aid transparency
    • Dr Sylvia Meek
    • Annual reviews
    • Policies and procedures
    • Careers
    • Tenders
    • Contact us
    • Malaria Consortium U.S.
  • Support us
© 2021 Malaria Consortium | Charity No. 1099776 | Company No. 4785712 | Privacy notice | Modern Slavery Statement